- Home
- GLUE vs FDMT Comparison
GLUE vs FDMT Comparison
Compare GLUE & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- FDMT
- Stock Information
- Founded
- GLUE 2019
- FDMT 2013
- Country
- GLUE United States
- FDMT United States
- Employees
- GLUE N/A
- FDMT N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- GLUE Health Care
- FDMT Health Care
- Exchange
- GLUE Nasdaq
- FDMT Nasdaq
- Market Cap
- GLUE 475.5M
- FDMT 420.7M
- IPO Year
- GLUE 2021
- FDMT 2020
- Fundamental
- Price
- GLUE $6.93
- FDMT $6.31
- Analyst Decision
- GLUE Buy
- FDMT Buy
- Analyst Count
- GLUE 3
- FDMT 11
- Target Price
- GLUE $12.67
- FDMT $42.80
- AVG Volume (30 Days)
- GLUE 1.8M
- FDMT 1.0M
- Earning Date
- GLUE 11-07-2024
- FDMT 11-13-2024
- Dividend Yield
- GLUE N/A
- FDMT N/A
- EPS Growth
- GLUE N/A
- FDMT N/A
- EPS
- GLUE N/A
- FDMT N/A
- Revenue
- GLUE $14,975,000.00
- FDMT $17,000.00
- Revenue This Year
- GLUE N/A
- FDMT N/A
- Revenue Next Year
- GLUE N/A
- FDMT $87.55
- P/E Ratio
- GLUE N/A
- FDMT N/A
- Revenue Growth
- GLUE N/A
- FDMT N/A
- 52 Week Low
- GLUE $3.21
- FDMT $5.58
- 52 Week High
- GLUE $12.40
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- GLUE 39.61
- FDMT 36.69
- Support Level
- GLUE $6.15
- FDMT $5.58
- Resistance Level
- GLUE $7.95
- FDMT $7.58
- Average True Range (ATR)
- GLUE 0.88
- FDMT 0.46
- MACD
- GLUE -0.34
- FDMT -0.06
- Stochastic Oscillator
- GLUE 17.18
- FDMT 34.93
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.